§ Federal grant opportunity · PA-25-253
Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)
National Institutes of Health is accepting applications for Exploratory Grants in Cancer Control (R21 Clinical Trial Optional). The deadline is September 7, 2028 and the published award range is Award amount not published.
Key facts
- Funder
- National Institutes of Health
- Application deadline
- September 7, 2028
- Award range
- Award amount not published
- Eligibility
- Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
- Geography
- United States
- Focus areas
- Education, Health
- Opportunity number
- PA-25-253
Program overview
This funding opportunity announcement (FOA) encourages the submission of exploratory/developmental research grant (R21) applications that focus on different aspects of cancer control by modifying behavior, screening, and understanding etiologic factors contributing to the development of cancer, and developing ways to control cancer. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance population-based cancer research, such as the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (epidemiologic, biomedical, behavioral, health care delivery or clinical).
How to apply
- Confirm your organization meets the eligibility criteria above.
- Read the full funding opportunity announcement from National Institutes of Health.
- Draft your narrative against the funder's stated priorities and review criteria.
- Submit before September 7, 2028, allowing time for registration and validation.
Related grant opportunities
- Method to Extend Research in Time (MERIT) Award Extension Request (Type 4 eSubmission Clinical Trial Optional)
- Limited Competition: Superfund Hazardous Substance Research and Training Program (P42 Clinical Trial Optional)
- Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)
- NIGMS Institutional Biomedical Undergraduate Research Training (BURT) Program (T34)
- Avant Garde/Avenir Awards for Investigators Conducting High Risk/High Reward Research on HIV and Substance Use (or Substance Use Disorders) (DP1 Clinical Trial Optional)
Find every grant your organization qualifies for
Mavenly scores this opportunity against your mission, geography, and funding history — then drafts the proposal with you and tracks the deadline through submission and reporting.